Natural vs synthetic surfactants in neonatal respiratory distress syndrome

Drugs

Volumn 51, Issue 2, 1996, Pages 226-237

  Halliday, Henry L ^a,b  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; SURFACTANT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG DYSPLASIA; META ANALYSIS; NEWBORN; NEWBORN MORTALITY; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; RETROLENTAL FIBROPLASIA; REVIEW;

EID: 0030044418     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651020-00004     Document Type: Review

References (48)

1. Morley CJ, Bangham AD, Miller N, et al. Dry artificial surfactant and its effect on very premature babies. Lancet 1981; 1: 64-8
2. Fujiwara T, Chida S, Watabe YJ, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-9
3. Phibbs RH, Ballard RA, Clements JA, et al. Initial clinical trial of Exosurf, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics 1991; 88: 1-9
4. Halliday HL, McClure G, Reid MMcC, et al. Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet 1984; 1: 476-8
5. Soll RF, Hoekstra RA, Fangman JJ, et al. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Pediatrics 1990; 85: 1092-102
6. Gortner L, Bernsau U, Hellwege HH, et al. A multicenter randomized controlled clinical trial of bovine surfactant for prevention of respiratory distress syndrome. Lung 1990; 168 Suppl.: 864-9
7. Enhorning G, Shennan A, Possmayer F, et al. Prevention of neonatal respiratory distress syndrome of tracheal instillation of surfactant: a randomized clinical trial. Pediatrics 1985; 76: 145-53
8. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988; 82: 683-91
9. Hallman M, Merritt TA, Jarvenpaa AL, et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 1985; 106: 963-9
10. Dechant KL, Faulds D. Colfosceril palmitate: a review of the therapeutic efficacy and clinical tolerability of a synthetic preparation (Exosurf® Neonatal™) in neonatal respiratory distress syndrome. Drugs 1991; 42: 877-94
11. Wiseman LR, Bryson HM. Porcine-derived lung surfactant: a review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf®) in neonatal respiratory distress syndrome. Drugs 1994; 48: 386-403
12. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861-8
13. Speer CP, Halliday HL. Surfactant therapy in the newborn. Curr Paediatr 1994; 4: 5-9
14. Soll RF, McQueen MC. Respiratory distress syndrome. In: Sinclair JC, Bracken MB, editors. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 325-58
15. Halliday HL. Other acute lung disorders. In: Sinclair JC, Bracken MB, editors. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 359-84
16. Cochrane Pregnancy and Childbirth Database. Update software. Oxford: Cochrane Collaboration, 1994
17. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 1995; 65 Suppl. 1: 32-47
18. Alvarado M, Hingre R, Hakanson D, et al. Clinical trial of Survanta vs Exosurf therapy in infants <1500g with respiratory distress syndrome (RDS) [abstract no. 1865]. Pediatr Res 1993; 33: 314
19. Bloom BT, Delmore P, Kattwinkel J, et al. Randomized double-blind multicenter trial of Survanta (SURV) and Infasurf (IS) [abstract no. 1942]. Pediatr Res 1994; 35: 326
20. Cotton RB, Law AB, Lindstrom DP, et al. Differential effects of synthetic and bovine surfactants on lung volume and oxygenation in premature infants with RDS [abstract no. 1812]. Pediatr Res 1992; 31: 304
21. Grauaug A, Kohan R, Sly P, et al. Exosurf and Survanta - are there advantages of one over the other when used as rescue therapy? [abstract no. 1993]. Pediatr Res 1994; 35: 335
22. Horbar JD, Wright LL, Soll RF, et al., for the National Institute of Child Health and Human Development Neonatal Research Network. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993; 123: 757-66
23. Hudak ML, Matteson FJ, Baus JA, et al. Infasurf V. Exosurf for the prophylaxis of RDS: a ten center randomized double-masked comparison trial [abstract no. 1369]. Pediatr Res 1994; 35: 231
24. Hudak ML, Matteson EJ, Baus JA, et al. Infasurf V. Exosurf for the treatment of RDS: a 21 center randomized double-masked comparison trial [abstract no. 1370]. Pediatr Res 1994; 35: 231
25. Modanlou HD, Beharry K, Norris K, et al. Comparative efficacy of Survanta (Surv) and Exosurf (Exo) on early clinical course of respiratory distress syndrome (RDS) [abstract no. 2056]. Pediatr Res 1994; 35: 345
26. Modanlou H, Beharry K, Norris K, et al. Comparative effects of Survanta (Surv) and Exosurf (Exo) on the outcome of respiratory distress syndrome (RDS) [abstract no. 1436]. Pediatr Res 1994; 35: 242
27. Pearlman SA, Leef KH, Stefano JL, et al. A randomized trial comparing Exosurf VS. Survanta in the treatment of neonatal RDS [abstract no. 2017]. Pediatr Res 1993; 33: 340
28. Rollins M, Jenkins J, Tubman R, et al. Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 1993; 21: 341-7
29. Sehgal SS, Ewing CK, Richards T, et al. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994; 84: 46-52
30. Speer CP, Gefeller O, Groneck P, et al. Randomized clinical trial of surfactant therapy for neonatal respiratory distress syndrome: comparison of two treatment regimens with natural surfactant preparations. Arch Dis Child 1995; 72: F8-13
31. Stenson BJ, Glover RM, Parry GJ, et al. Static respiratory compliance in the newborn: III. Early changes after exogenous surfactant treatment. Arch Dis Child 1994; 70: F19-24
32. Vermont Oxford Trials Network. A multicenter randomized trial comparing synthetic surfactant to modified bovine surfactant in the treatment of neonatal respiratory distress syndrome [abstract no. 1542]. Pediatr Res 1994; 35: 259
33. Grauaug A, Kohan R, Milner G, et al. Pulmonary function changes using Exosurf or Survanta - a randomised trial [abstract no. 1984]. Pediatr Res 1995; 37: 333
34. Sinclair JC. Assessing evidence concerning treatment and prevention of diseases of the newborn. In: Sinclair JC, Bracken MB, editors. Effective care of the newborn infant, Oxford: Oxford University Press, 1992: 3-12
35. Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweights less than 1500 gm. J Pediatr 1978; 92: 529-34
36. An international classification of retinopathy of prematurity [editorial]. Pediatrics 1984; 74: 127-33
37. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal, 1989
38. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4
39. Cummings JJ, Holm BA, Hudak BB. A controlled clinical comparison of four different surfactant preparations in surfactant deficient preterm lambs. Am Rev Respir Dis 1992; 145: 999-1004
40. Corcoran JD, Berggren P, Sun B, et al. Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits. Arch Dis Child 1994; 71: F165-9
41. Raju TNK, Langenberg R. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993; 123: 603-10
42. Stevenson DK, Walther F, Long WA and the American Exosurf Neonatal Study Group I. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500-699 grams. J Pediatr 1992; 120: S3-12
43. Rankin SJA, Tubman TRJ, Halliday HL, et al. Retinopathy of prematurity in surfactant treated infants. Br J Ophthalmol 1992; 76: 202-4
44. Tubman TRJ, Rankin SJ, Halliday HL, et al. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Biol Neonate 1992; 61 Suppl. 1: 54-8
45. Halliday HL. Surfactant replacement therapy. Pediatr Pulmonol 1995; Suppl. 11: 96-7
46. Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses? BMJ 1994; 309: 1007-10
47. Hall SB, Venkitarann AR, Whitsett JA, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992; 145: 24-30
48. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7: 372-91